These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12052815)

  • 21. Demand for prostate specific antigen testing in primary care. Screening through back passage as well as back door?
    Hopcroft K
    BMJ; 2002 Mar; 324(7336):547. PubMed ID: 11872566
    [No Abstract]   [Full Text] [Related]  

  • 22. Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
    Hayes JH; Barry MJ; Kantoff PW; Stahl JE
    BJU Int; 2007 Sep; 100(3):486-8. PubMed ID: 17669139
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate specific antigen and screening for early prostate cancer.
    Davidson P
    N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
    [No Abstract]   [Full Text] [Related]  

  • 24. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening for prostate cancer. Consider the harms.
    Bewley S
    BMJ; 2010 Oct; 341():c5811. PubMed ID: 20978045
    [No Abstract]   [Full Text] [Related]  

  • 26. A risk-stratified approach to prostate-specific antigen screening.
    Keto CJ; Freedland SJ
    Eur Urol; 2011 Apr; 59(4):506-8. PubMed ID: 21292387
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostate specific antigen screening and active surveillance in the elderly.
    Konety BR
    J Urol; 2009 Apr; 181(4):1534-5. PubMed ID: 19230925
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer screening with PSA: "Aequanimitas".
    Sadi MV
    Int Braz J Urol; 2013; 39(4):447-53. PubMed ID: 24054394
    [No Abstract]   [Full Text] [Related]  

  • 29. Is a screening interval of every 4 years for prostate cancer acceptable?
    Crawford ED
    J Natl Cancer Inst; 2007 Sep; 99(17):1279-80. PubMed ID: 17728212
    [No Abstract]   [Full Text] [Related]  

  • 30. Screening for prostate cancer.
    Raffle AE
    Br J Hosp Med; 1997 Nov 19-Dec 9; 58(10):484, 486. PubMed ID: 10193448
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate-specific antigen and prostate cancer prognosis.
    Church TR
    J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
    [No Abstract]   [Full Text] [Related]  

  • 32. Screening for prostate cancer. The case against.
    Donovan JL; Hamdy FC; Neal DE;
    Ann R Coll Surg Engl; 2005 Mar; 87(2):90-1; discussion 88. PubMed ID: 15832433
    [No Abstract]   [Full Text] [Related]  

  • 33. If less is more, which outcomes should be presented in facilitating prostate cancer screening decision making?
    Partin MR; Powell AA
    JAMA Intern Med; 2013 Sep; 173(17):1656-7. PubMed ID: 24061391
    [No Abstract]   [Full Text] [Related]  

  • 34. Screening for prostate cancer remains controversial.
    Neal DE; Donovan JL; Martin RM; Hamdy FC
    Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 36. One man at a time--resolving the PSA controversy.
    McNaughton-Collins MF; Barry MJ
    N Engl J Med; 2011 Nov; 365(21):1951-3. PubMed ID: 22029758
    [No Abstract]   [Full Text] [Related]  

  • 37. If less is more, which outcomes should be presented in facilitating prostate cancer screening decision making? - reply.
    Pignone MP
    JAMA Intern Med; 2013 Sep; 173(17):1657. PubMed ID: 24061393
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Roobol MJ; Schröder FH
    J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient information: should I have a PSA screening?
    JAAPA; 2012 Jul; 25(7):58. PubMed ID: 22894039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.